{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:36:49Z","timestamp":1792431409701,"version":"4.5.0"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"10","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vorinostat is a histone deacetylase inhibitor that induces differentiation, growth arrest, and\/or apoptosis of malignant cells both in vitro and in vivo and has shown clinical responses in \u223c30% of patients with advanced mycosis fungoides and Se\u0301zary syndrome cutaneous T-cell lymphoma (CTCL). The purpose of this study was to identify biomarkers predictive of vorinostat response in CTCL using preclinical model systems and to assess these biomarkers in clinical samples. The signal transducer and activator of transcription (STAT) signaling pathway was evaluated. The data indicate that persistent activation of STAT1, STAT3, and STAT5 correlate with resistance to vorinostat in lymphoma cell lines. Simultaneous treatment with a pan-Janus-activated kinase inhibitor resulted in synergistic antiproliferative effect and down-regulation of the expression of several antiapoptotic genes. Immunohistochemical analysis of STAT1 and phosphorylated tyrosine STAT3 (pSTAT3) in skin biopsies obtained from CTCL patients enrolled in the vorinostat phase IIb trial showed that nuclear accumulation of STAT1 and high levels of nuclear pSTAT3 in malignant T cells correlate with a lack of clinical response. These results suggest that deregulation of STAT activity plays a role in vorinostat resistance in CTCL, and strategies that block this pathway may improve vorinostat response. Furthermore, these findings may be of prognostic value in predicting the response of CTCL patients to vorinostat. [Cancer Res 2008;68(10):3785\u201394]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-6091","type":"journal-article","created":{"date-parts":[[2008,5,15]],"date-time":"2008-05-15T14:14:48Z","timestamp":1210860888000},"page":"3785-3794","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":154,"title":["Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma"],"prefix":"10.1158","volume":"68","author":[{"given":"Valeria R.","family":"Fantin","sequence":"first","affiliation":[{"name":"1Merck Research Laboratories;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Loboda","sequence":"additional","affiliation":[{"name":"3Merck Research Laboratories, West Point, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cloud P.","family":"Paweletz","sequence":"additional","affiliation":[{"name":"1Merck Research Laboratories;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Hendrickson","sequence":"additional","affiliation":[{"name":"4Merck Research Laboratories, Rahway, New Jersey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline W.","family":"Pierce","sequence":"additional","affiliation":[{"name":"1Merck Research Laboratories;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Roth","sequence":"additional","affiliation":[{"name":"1Merck Research Laboratories;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Li","sequence":"additional","affiliation":[{"name":"1Merck Research Laboratories;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Gooden","sequence":"additional","affiliation":[{"name":"1Merck Research Laboratories;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Korenchuk","sequence":"additional","affiliation":[{"name":"1Merck Research Laboratories;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli S.","family":"Hou","sequence":"additional","affiliation":[{"name":"3Merck Research Laboratories, West Point, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Harrington","sequence":"additional","affiliation":[{"name":"1Merck Research Laboratories;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Randolph","sequence":"additional","affiliation":[{"name":"5Merck & Co., Inc., Seattle, Washington;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Reilly","sequence":"additional","affiliation":[{"name":"1Merck Research Laboratories;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Ware","sequence":"additional","affiliation":[{"name":"1Merck Research Laboratories;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall E.","family":"Kadin","sequence":"additional","affiliation":[{"name":"2Department of Pathology, Harvard Medical School, Boston, Massachusetts;"},{"name":"6Department of Dermatology and Skin Surgery, Roger Williams Medical Center, Providence, Rhode Island; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley R.","family":"Frankel","sequence":"additional","affiliation":[{"name":"7Merck Research Laboratories, Upper Gwynedd, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria M.","family":"Richon","sequence":"additional","affiliation":[{"name":"1Merck Research Laboratories;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,5,15]]},"reference":[{"key":"2022061700293943200_B1","doi-asserted-by":"crossref","unstructured":"Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest\u20082005; 115: 798\u2013812.","DOI":"10.1172\/JCI24826"},{"key":"2022061700293943200_B2","doi-asserted-by":"crossref","unstructured":"Demierre MF, Kim YH, Zackheim HS. Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am\u20082003; 17: 1485\u2013507.","DOI":"10.1016\/S0889-8588(03)00111-4"},{"key":"2022061700293943200_B3","doi-asserted-by":"crossref","unstructured":"Foss F. Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches. Leuk Lymphoma\u20082003; 44 Suppl 3: S55\u201361.","DOI":"10.1080\/10428190310001623757"},{"key":"2022061700293943200_B4","doi-asserted-by":"crossref","unstructured":"Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A\u20081998; 95: 3003\u20137.","DOI":"10.1073\/pnas.95.6.3003"},{"key":"2022061700293943200_B5","doi-asserted-by":"crossref","unstructured":"Richon VM. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer\u20082006; 95 Suppl 1: S2\u20136.","DOI":"10.1038\/sj.bjc.6603463"},{"key":"2022061700293943200_B6","doi-asserted-by":"crossref","unstructured":"Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood\u20082007; 109: 31\u20139.","DOI":"10.1182\/blood-2006-06-025999"},{"key":"2022061700293943200_B7","doi-asserted-by":"crossref","unstructured":"Olsen EA, Kim YH, Kuzel TM, et al. A phase IIb multicenter trial of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with persistent, progressive or treatment refractory mycosis fungoides or se\u0301zary syndrome subtypes of cutaneous T-cell lymphoma. J Clin Oncol\u20082007; 25: 3109\u201315.","DOI":"10.1200\/JCO.2006.10.2434"},{"key":"2022061700293943200_B8","doi-asserted-by":"crossref","unstructured":"Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene\u20082007; 26: 1351\u20136.","DOI":"10.1038\/sj.onc.1210204"},{"key":"2022061700293943200_B9","doi-asserted-by":"crossref","unstructured":"Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discov\u20082007; 6: 21\u20132.","DOI":"10.1038\/nrd2227"},{"key":"2022061700293943200_B10","unstructured":"Johnstone RW. Suberanilohydroxamic acid. Aton Pharma. IDrugs\u20082004; 7: 674\u201382."},{"key":"2022061700293943200_B11","doi-asserted-by":"crossref","unstructured":"Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol\u20081998; 16: 293\u2013322.","DOI":"10.1146\/annurev.immunol.16.1.293"},{"key":"2022061700293943200_B12","doi-asserted-by":"crossref","unstructured":"Darnell JE, Jr. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J Interferon Cytokine Res\u20081998; 18: 549\u201354.","DOI":"10.1089\/jir.1998.18.549"},{"key":"2022061700293943200_B13","doi-asserted-by":"crossref","unstructured":"Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer\u20082004; 4: 97\u2013105.","DOI":"10.1038\/nrc1275"},{"key":"2022061700293943200_B14","unstructured":"Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res\u20082002; 8: 945\u201354."},{"key":"2022061700293943200_B15","doi-asserted-by":"crossref","unstructured":"Frank DA. STAT signaling in cancer: insights into pathogenesis and treatment strategies. In: Signal transduction in cancer. Secaucus: Kluwer Academic Publishers; 2002. p. 267\u201391.","DOI":"10.1007\/0-306-48158-8_11"},{"key":"2022061700293943200_B16","doi-asserted-by":"crossref","unstructured":"Verma A, Kambhampati S, Parmar S, Platanias LC. Jak family of kinases in cancer. Cancer Metastasis Rev\u20082003; 22: 423\u201334.","DOI":"10.1023\/A:1023805715476"},{"key":"2022061700293943200_B17","doi-asserted-by":"crossref","unstructured":"Li L, Shaw PE. A STAT3 dimer formed by inter-chain disulphide bridging during oxidative stress. Biochem Biophys Res Commun\u20082004; 322: 1005\u201311.","DOI":"10.1016\/j.bbrc.2004.08.014"},{"key":"2022061700293943200_B18","doi-asserted-by":"crossref","unstructured":"Valentino L, Pierre J. JAK\/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol\u20082006; 71: 713\u201321.","DOI":"10.1016\/j.bcp.2005.12.017"},{"key":"2022061700293943200_B19","doi-asserted-by":"crossref","unstructured":"Mitchell TJ, John S. Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology\u20082005; 114: 301\u201312.","DOI":"10.1111\/j.1365-2567.2005.02091.x"},{"key":"2022061700293943200_B20","doi-asserted-by":"crossref","unstructured":"Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene\u20082000; 19: 2474\u201388.","DOI":"10.1038\/sj.onc.1203527"},{"key":"2022061700293943200_B21","doi-asserted-by":"crossref","unstructured":"Bromberg J. Stat proteins and oncogenesis. J Clin Invest\u20082002; 109: 1139\u201342.","DOI":"10.1172\/JCI0215617"},{"key":"2022061700293943200_B22","doi-asserted-by":"crossref","unstructured":"Zhang Q, Nowak I, Vonderheid EC, et al. Activation of Jak\/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci U S A\u20081996; 93: 9148\u201353.","DOI":"10.1073\/pnas.93.17.9148"},{"key":"2022061700293943200_B23","doi-asserted-by":"crossref","unstructured":"Sommer VH, Clemmensen OJ, Nielsen O, et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia\u20082004; 18: 1288\u201395.","DOI":"10.1038\/sj.leu.2403385"},{"key":"2022061700293943200_B24","doi-asserted-by":"crossref","unstructured":"Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell\u20081999; 98: 295\u2013303.","DOI":"10.1016\/S0092-8674(00)81959-5"},{"key":"2022061700293943200_B25","doi-asserted-by":"crossref","unstructured":"Ikuta K, Takemura K, Kihara M, et al. Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells. Oncol Rep\u20082005; 13: 217\u201322.","DOI":"10.3892\/or.13.6.1229"},{"key":"2022061700293943200_B26","doi-asserted-by":"crossref","unstructured":"Roberts D, Schick J, Conway S, et al. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer\u20082005; 92: 1149\u201358.","DOI":"10.1038\/sj.bjc.6602447"},{"key":"2022061700293943200_B27","doi-asserted-by":"crossref","unstructured":"Gritsko T, Williams A, Turkson J, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res\u20082006; 12: 11\u20139.","DOI":"10.1158\/1078-0432.CCR-04-1752"},{"key":"2022061700293943200_B28","unstructured":"Khoury JD, Medeiros LJ, Rassidakis GZ, et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res\u20082003; 9: 3692\u20139."},{"key":"2022061700293943200_B29","unstructured":"Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res\u20082003; 9: 316\u201326."},{"key":"2022061700293943200_B30","doi-asserted-by":"crossref","unstructured":"Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene\u20082001; 20: 1981\u20139.","DOI":"10.1038\/sj.onc.1204265"},{"key":"2022061700293943200_B31","doi-asserted-by":"crossref","unstructured":"Hughes TR, Mao M, Jones AR, et al. Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol\u20082001; 19: 342\u20137.","DOI":"10.1038\/86730"},{"key":"2022061700293943200_B32","doi-asserted-by":"crossref","unstructured":"van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature\u20082002; 415: 530\u20136.","DOI":"10.1038\/415530a"},{"key":"2022061700293943200_B33","doi-asserted-by":"crossref","unstructured":"Fantin VR, Berardi MJ, Babbe H, et al. A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells. Cancer Res\u20082005; 65: 6891\u2013900.","DOI":"10.1158\/0008-5472.CAN-05-0395"},{"key":"2022061700293943200_B34","doi-asserted-by":"crossref","unstructured":"Fisher R. On the interpretation of x2 from contingency tables, and the calculation of P. J R Stat Soc\u20081922; 85: 87\u201394.","DOI":"10.2307\/2340521"},{"key":"2022061700293943200_B35","doi-asserted-by":"crossref","unstructured":"Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol\u20082005; 23: 3923\u201331.","DOI":"10.1200\/JCO.2005.14.167"},{"key":"2022061700293943200_B36","unstructured":"Ni X, Hazarika P, Zhang C, et al. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T-lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res\u20082001; 7: 2682\u201392."},{"key":"2022061700293943200_B37","doi-asserted-by":"crossref","unstructured":"Shao RH, Tian X, Gorgun G, et al. Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2R\u03b2 gene. Leuk Res\u20082002; 26: 1077\u201383.","DOI":"10.1016\/S0145-2126(02)00059-0"},{"key":"2022061700293943200_B38","doi-asserted-by":"crossref","unstructured":"Zhang C, Richon V, Ni X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol\u20082005; 125: 1045\u201352.","DOI":"10.1111\/j.0022-202X.2005.23925.x"},{"key":"2022061700293943200_B39","doi-asserted-by":"crossref","unstructured":"Nishizuka S, Charboneau L, Young L, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A\u20082003; 100: 14229\u201334.","DOI":"10.1073\/pnas.2331323100"},{"key":"2022061700293943200_B40","doi-asserted-by":"crossref","unstructured":"Eriksen KW, Kaltoft K, Mikkelsen G, et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia\u20082001; 15: 787\u201393.","DOI":"10.1038\/sj.leu.2402093"},{"key":"2022061700293943200_B41","doi-asserted-by":"crossref","unstructured":"Nielsen M, Kaltoft K, Nordahl M, et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A\u20081997; 94: 6764\u20139.","DOI":"10.1073\/pnas.94.13.6764"},{"key":"2022061700293943200_B42","doi-asserted-by":"crossref","unstructured":"Rascle A, Johnston JA, Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol\u20082003; 23: 4162\u201373.","DOI":"10.1128\/MCB.23.12.4162-4173.2003"},{"key":"2022061700293943200_B43","doi-asserted-by":"crossref","unstructured":"Xu M, Nie L, Kim SH, Sun XH. STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C\/EBP\u03b2. EMBO J\u20082003; 22: 893\u2013904.","DOI":"10.1093\/emboj\/cdg094"},{"key":"2022061700293943200_B44","doi-asserted-by":"crossref","unstructured":"Catania A, Iavarone C, Carlomagno SM, Chiariello M. Selective transcription and cellular proliferation induced by PDGF require histone deacetylase activity. Biochem Biophys Res Commun\u20082006; 343: 544\u201354.","DOI":"10.1016\/j.bbrc.2006.03.013"},{"key":"2022061700293943200_B45","unstructured":"Klampfer L, Huang J, Sasazuki T, et al. Inhibition of interferon \u03b3 signaling by the short chain fatty acid butyrate. Mol Cancer Res\u20082003; 1: 855\u201362."},{"key":"2022061700293943200_B46","doi-asserted-by":"crossref","unstructured":"Wang R, Cherukuri P, Luo J. Activation of Stat3 sequence-specific DNA binding and transcription by p300\/CREB-binding protein-mediated acetylation. J Biol Chem\u20082005; 280: 11528\u201334.","DOI":"10.1074\/jbc.M413930200"},{"key":"2022061700293943200_B47","doi-asserted-by":"crossref","unstructured":"Sakamoto S, Potla R, Larner AC. Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes. J Biol Chem\u20082004; 279: 40362\u20137.","DOI":"10.1074\/jbc.M406400200"},{"key":"2022061700293943200_B48","doi-asserted-by":"crossref","unstructured":"Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity\u20081999; 10: 105\u201315.","DOI":"10.1016\/S1074-7613(00)80011-4"},{"key":"2022061700293943200_B49","doi-asserted-by":"crossref","unstructured":"Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest\u20082001; 107: 351\u201362.","DOI":"10.1172\/JCI9940"},{"key":"2022061700293943200_B50","doi-asserted-by":"crossref","unstructured":"Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood\u20082003; 101: 1535\u201342.","DOI":"10.1182\/blood-2002-07-2130"},{"key":"2022061700293943200_B51","doi-asserted-by":"crossref","unstructured":"Witkiewicz A, Raghunath P, Wasik A, et al. Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma. Hum Pathol\u20082007; 38: 462\u20137.","DOI":"10.1016\/j.humpath.2006.09.012"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/10\/3785\/2592307\/3785.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/10\/3785\/2592307\/3785.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T01:27:23Z","timestamp":1655429243000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/10\/3785\/540685\/Constitutive-Activation-of-Signal-Transducers-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,15]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2008,5,15]]},"published-print":{"date-parts":[[2008,5,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-6091","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22370540.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370537.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370534.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370552.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370537","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370546","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370534","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370549.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370546.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370531.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370549","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370540","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370555.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370555","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370531","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22370552","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6496430.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6496430","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,15]]}}}